Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Genentech, Inc.; Janssen Pharmaceuticals; Eli Lilly and Company; and Pharmacyclics LLC, an AbbVie Company.

Community Practice Connections™: How Are We Meeting the Needs of Patients With CLL Across Lines of Care?

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

It is estimated that approximately 21,200 patients will be diagnosed with chronic lymphocytic leukemia (CLL) in 2021, and approximately 4,300 will succumb to the disease. For many years, available treatments were limited to highly toxic chemotherapy-based regimens, and patient outcomes were less than ideal. In the past several years, a greater understanding of the biology of CLL has led to a number of new and emerging agents that have revolutionized the treatment for this disease.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the recent virtual satellite symposium, How Are We Meeting the Needs of Patients With CLL Across Lines of Care? held in September 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with CLL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the virtual symposium and to help reinforce learnings for those who did.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from Genentech, Inc.; Janssen Pharmaceuticals; Eli Lilly and Company; and Pharmacyclics LLC, an AbbVie Company.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with chronic lymphocytic leukemia (CLL). Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with CLL are also invited to attend.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Determine risk stratification methods in patients with CLL and application of patient risk categories for treatment identification
  • Integrate evolving practices in the management of patients with CLL through multiple lines of therapy, integrating the influence of previous regimens on subsequent decision-making
  • Discuss the role of minimal residual–disease (MRD) testing as a tool for prognosis and treatment selection in patients with CLL
  • Evaluate strategies to proactively mitigate and manage treatment-related adverse events that occur with current and emerging approaches, including combination treatment strategies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
 

Faculty

Anthony Mato, MD, MSCE
Anthony Mato, MD, MSCE
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, AbbVie, Acerta Pharma/AstraZeneca, Sunesis Pharmaceuticals, Loxo Oncology, Regeneron Pharmaceuticals, DTRM; Consultant: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, AbbVie, Acerta Pharma/AstraZeneca, Sunesis Pharmaceuticals, Loxo Oncology, Regeneron Pharmaceuticals, Johnson & Johnson, Celgene; Other: Advisory Board: Data and Safety Monitoring Board: TG Therapeutics, Celgene.

Nitin Jain, MD
Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, Bristol Myers Squibb, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision BioSciences, Aprea Therapeutics, Fate Therapeutics; Consultant: Pharmacyclics, Janssen Pharmaceuticals, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Laboratoires Servier, Precision BioSciences, BeiGene, TG Therapeutics, ADC Therapeutics.

William G. Wierda, MD, PhD
William G. Wierda, MD, PhD
DB Lane Cancer Research Distinguished Professor
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research support: GlaxoSmithKline/Novartis, AbbVie, Genentech, Pharmacyclics, Acerta Pharma/AstraZeneca, Gilead Sciences, Juno Therapeutics, Kite Pharma, Sunesis Pharmaceuticals, Miragen Therapeutics, Oncternal Therapeutics, Cyclacel Pharmaceuticals, Loxo Oncology, Janssen Pharmaceuticals, Xencor.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By